More than 60% of the Phelan McDermid patients investigated here have alterations in the CSF degeneration markers tau protein and amyloid-ß without exhibiting the typical pattern seen in patients with Alzheimer disease. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.